Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Benitec Biopharma Inc.

Contributing Author

Recent Articles by Benitec Biopharma Inc.

Oct-28	Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 BNTC GlobeNewswire
Oct-05	Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study BNTC GlobeNewswire
Sep-14	Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update BNTC BNTC -8.53% GlobeNewswire
May-14	Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update BNTC GlobeNewswire
Apr-28	Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting BNTC GlobeNewswire
Mar-10	Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) BNTC GlobeNewswire
Mar-09	Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference BNTC +10.67% GlobeNewswire
Feb-23	Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference BNTC GlobeNewswire
Feb-12	Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update BNTC GlobeNewswire
Jan-11	Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response BNTC GlobeNewswire
Nov-14	Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update BNTC GlobeNewswire
Nov-06	Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering BNTC -23.95% GlobeNewswire
Nov-05	Benitec Biopharma Inc. Announces Proposed Public Offering BNTC GlobeNewswire
Nov-03	Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 BNTC GlobeNewswire
Nov-03	Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors BNTC GlobeNewswire
Nov-02	Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy BNTC GlobeNewswire
Sep-22	Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update BNTC GlobeNewswire
Jul-09	Benitec Biopharma Provides Operational Updates BNTC +9.67% GlobeNewswire
May-14	Benitec Biopharma Releases Third Quarter 2025 Financial Results BNTC GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)